Leila's research interests
include rare disease research ethics and the regulation of new technologies in healthcare and public health.
Not exact matches
And in the United States, the National Human Genome
Research Institute in Bethesda, Maryland, recently funded three Mendelian Disorders Sequencing Centers that will apply genome sequencing to diagnosing thousands of patients with a wider range of
rare diseases,
including intellectual disability and developmental delay.
Items worthy of mention in this context
include new drugs for cancer, new therapies for
rare diseases, progress in HIV medications, and stem cell
research.
This week's headlines
include: GSK slims portfolio with sale of
rare disease gene therapy drugs, The Focus Shifts in Alzheimer's
Research, Healing process after breast cancer surgery may trigger...
With a team of over 200 researchers, Sanford
Research is comprised of eight groups that bridge bench, translational and clinical research including: Cancer Biology and Immunotherapies, Pediatrics and Rare Diseases, Diabetes, Cellular Therapies and Stem Cell Biology, Enabling Technology, Environmental Influences on Health and Disease, Genetics and Genomics, and Population
Research is comprised of eight groups that bridge bench, translational and clinical
research including: Cancer Biology and Immunotherapies, Pediatrics and Rare Diseases, Diabetes, Cellular Therapies and Stem Cell Biology, Enabling Technology, Environmental Influences on Health and Disease, Genetics and Genomics, and Population
research including: Cancer Biology and Immunotherapies, Pediatrics and
Rare Diseases, Diabetes, Cellular Therapies and Stem Cell Biology, Enabling Technology, Environmental Influences on Health and
Disease, Genetics and Genomics, and Population Health.
Some
research efforts are closer to clinical implementation,
including developing improvements in clinical management of
rare diseases and trials of small molecule therapies for inherited and mosaic genetic disorders.
Summary: A two day meeting to demonstrate to the wider scientific community where the IMPC is trying to go and how to
include clinical scientists, geneticists and the
rare disease research community, followed by two simultaneous one day workshops (phenotyping and EUCOMMTOOLS) to plan for Phase II phenotyping and discuss production technology development Attended by: IMPC members, corporate sponsors, external delegates, EUCOMMTOOLS members and IKMC members Hosted / funded by: Infrafrontier, EUCOMMTOOLS, CNR Monterotondo
To tackle these goals, following extensive and collective discussion and prioritization, the Consortium defined its new roadmap for 2018 which
includes actions to accelerate
research and development in
rare diseases, and to remove numerous barriers and bottlenecks.
The Area of Genomic Medicine is devised as a scientific production structure which will preferably
include research groups centred on work in the area of genetic epidemiology of some of the main public health problems (cancer, autoimmune
diseases, cardiovascular
diseases, diabetes,
rare diseases, etc.).
Consent considerations for data sharing in MME
included both the ethical and legal differences between clinical and
research settings and the level of privacy risk involved in sharing varying amounts of
rare disease patient data to enable patient matches.